A Post-Marketing Surveillance Study to Evaluate the Safety Profile of AlvotereⓇ (Docetaxel) in Iranian Patients Diagnosed with Different Types of Cancers Receiving Chemotherapy

• Hlavní autoři: Farhad Shahi, Associate Professor (Autor), Farahnaz Vafaeezadeh, Post doctoral fellowship (Autor), Nafiseh Ansarinejad, Associate Professor (Autor), Alireza Ahmadi, Post doctoral fellowship (Autor), Ali Shahriari-Ahmadi, Associate Professor (Autor), Alireza Ghazizadeh, Associate Professor (Autor), Hassanali Vahedian Ardakani, Associate Professor (Autor), Mohammad Reza Ravanbod, Associate Professor (Autor), Sharareh Seifi, Associate Professor (Autor), Mohammad Foratyazdi, Associate Professor (Autor), Seyed Asadollah Mousavi, Associate Professor (Autor), Mansour Rajabi Vahid, Associate Professor (Autor), Hossein Rahimi, Associate Professor (Autor), Mohammad Seghatoleslami, Post doctoral fellowship (Autor), Seyed Mohsen Razavi, Associate Professor (Autor), Amir Houshang Pourkhani, Associate Professor (Autor), Davoud Babakhani, Post doctoral fellowship (Autor), Nassim Anjidani, Pharm. D. (Autor)
• Médium: Kniha
• Vydáno: Elsevier, 2022-01-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

ABSTRACT: Background: Docetaxel is a clinically well established antimitotic chemotherapy medication. Labeled docetaxel indications are breast cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, and prostate cancer. Objective: This is a Phase IV study to evaluate the safety pro...